CoChat

SARS-CoV-2–specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein

Open access
Keller, Michael D., Harris, Katherine M., Jensen-Wachspress, Mariah A., Kankate, Vaishnavi V., Lang, Haili, Lazarski, Christopher A., Durkee-Shock, Jessica, Lee, Ping-Hsien, Chaudhry, Kajal, Webber, Kathleen, Datar, Anushree, Terpilowski, Madeline, Reynolds, Emily K., Stevenson, Eva M., Val, Stephanie, Shancer, Zoe, Zhang, Nan, Ulrey, Robert, Ekanem, Uduak, Stanojevic, Maja, Geiger, Ashley, Liang, Hua, Hoq, Fahmida, Abraham, Allistair A., Hanley, Patrick J., Cruz, C. Russell, Ferrer, Kathleen, Dropulic, Lesia, Gangler, Krista, Burbelo, Peter D., Jones, R. Brad, Cohen, Jeffrey I., Bollard, Catherine M. · 2020 · Blood
Cited by 128

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

T-cell responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been described in recovered patients, and may be important for immunity following infection and vaccination as well as for the development of an adoptive immunotherapy for the treatment of immunocompromised individuals. In this report, we demonstrate that SARS-CoV-2–specific T cells can be expanded from convalescent donors and recognize immunodominant viral epitopes in conserved regions of membrane, spike, and nucleocapsid. Following in vitro expansion using a good manufacturing practice-compliant methodology (designed to allow the rapid translation of this novel SARS-CoV-2 T-cell therapy to the clinic), membrane, spike, and nucleocapsid peptides elicited interferon-γ production, in 27 (59%), 12 (26%), and 10 (22%) convalescent donors (respectively), as well as in 2 of 15 unexposed controls. We identified multiple polyfunctional CD4-restricted T-cell epitopes within a highly conserved region of membrane protein, which induced polyfunctional T-cell responses, which may be critical for the development of effective vaccine and T-cell therapies. Hence, our study shows that SARS-CoV-2 directed T-cell immunotherapy targeting structural proteins, most importantly membrane protein, should be feasible for the prevention or early treatment of SARS-CoV-2 infection in immunocompromised patients with blood disorders or after bone marrow transplantation to achieve antiviral control while mitigating uncontrolled inflammation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood.2020008488

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 128

Metadata

Authors
Keller, M. D., Harris, K. M., Jensen-Wachspress, M. A., Kankate, V. V., Lang, H., Lazarski, C. A., Durkee-Shock, J., Lee, P.-H., Chaudhry, K., Webber, K., Datar, A., Terpilowski, M., Reynolds, E. K., Stevenson, E. M., Val, S., Shancer, Z., Zhang, N., Ulrey, R., Ekanem, U., Stanojevic, M., Geiger, A., Liang, H., Hoq, F., Abraham, A. A., Hanley, P. J., Cruz, C. R., Ferrer, K., Dropulic, L., Gangler, K., Burbelo, P. D., Jones, R. B., Cohen, J. I., & Bollard, C. M.
Venue
Blood
Published
2020-12-17
Volume
136
Issue
25
Pages
2905-2917
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W3093885371
Cited by
128
References
13
FWCI
3.11
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.